TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04209790

Intervention type: RADIATION
Group type: OTHER
Intervention: Neoadjuvant chemoradiation
Description: Intensity modulation radiation therapy (IMRT) with a simultaneous integrated boost with Fixed-gantry IMRT, helical tomotherapy, or Vesicular Modulated Arc Therapy (VMAT) can be used. All photon treatments shall be delivered with megavoltage machines of a minimum energy of 6 Megavolt (MV) photons. Selection of the appropriate photon energy(ies) should be based on optimizing the radiation dose distribution within the target volume and minimizing dose to non-target normal tissue.

Intervention type: DRUG
Group type: OTHER
Intervention: Drug Therapy with Temozolomide (benzolamide) (Standard of Care)
Description: During Concomitant Radiation Therapy on the same day as the first fraction of radiotherapy. Temozolomide will be administered continuously from day 1 of radiotherapy to the last day of radiation at a daily oral dose of 75 mg/m2 for a maximum of 49 days. The drug will be administered orally daily during radiotherapy, as best tolerated by the patient. During weekends without radiotherapy (Saturday and Sunday), the drug will be taken in the morning. The dose will be determined using actual body surface area (BSA) as calculated in square meters at the beginning of the concomitant treatment. The BSA will be calculated from the height obtained at the pretreatment visit. Capsules of temozolomide are available in 5, 20, 100, 140, 180, and 250 mg. The daily dose will be rounded to the nearest 5 mg.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgery post Radiation and Temozolomide (benzolamide)
Description: Surgical resection of GBM will be done after radiation and Temozolomide treatment.
Study: NCT05251896

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Plasma-free procedure
Description: Use albumin solution, lactated Ringer's solution, normal saline as replacement fluid
Study: NCT01905527

Intervention type: OTHER
Intervention: Standard Services of Group A (Group A1)
Description: Support services provided in this group will include: Initial field nurse injection training visit; field nurse follow-up and subsequent visits; and follow-up phone calls at periodic intervals

Intervention type: OTHER
Intervention: Customized Services of Group A (Group A2)
Description: In addition to the initial field nurse injection training visit and follow-up call, subjects will select from support services including field nurse follow-up visits; follow-up phone calls; email and/or text reminders; subject self-assessment and use of treatment planning tools; and mail/e-mail educational materials.

Intervention type: OTHER
Intervention: Group B
Description: Support services provided in this group will include initial field nurse injection training visit and follow-up phone calls at periodic intervals.
Study: NCT00880113

Intervention type: PROCEDURE
Intervention: Non-contrast CT, CT-perfusion and CT-angiography
Description: Included patients will undergo one additional combined CT-scan (NCCT, CTP and CTA) on day 3 (+/- 2 days).
Study: NCT01609296

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IN.PACT Admiral™ Drug Eluting Balloon
Description: IN.PACT Admiral™ percutaneous transluminal angioplasty (PTA) paclitaxel drug eluting balloon.
Study: NCT04040140

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: APA Treatment
Description: Light touch using vaccaria seeds on corresponding ear points related to patient's pain.
Study: NCT04325568

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: PsyGist and Clinician Manual
Description: This is a pre-post test design aimed at conveying future genetic risk information to those at clinical high risk for psychosis. Participants will be assigned to either complete the Clinician Manual intervention (n= 27 participants) or PsyGist intervention (n=27 participants).

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: PsyGist and Clinician Manual
Description: This is a pre-post test design aimed at conveying future genetic risk information to those at clinical high risk for psychosis. Participants will be assigned to either complete the Clinician Manual intervention (n= 27 participants) or PsyGist intervention (n=27 participants).
Study: NCT04446338

Intervention type: DIAGNOSTIC_TEST
Intervention: Antibody Test
Description: Presence and Titer of Anti-Sars-CoV-2 Antbodies
Study: NCT02641418

Intervention type: OTHER
Group type: OTHER
Intervention: Supervised exercise programme
Description: supervised exercise programme
Study: NCT03601598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: SHR-1210 was administered 200mg iv every 2 weeks
Study: NCT01964170

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Goserelin
Description: subcutaneous
Study: NCT04223180

Intervention type: DEVICE
Intervention: Robotic assisted intervention
Description: Robotic treatment of the upper limb (30 sessions, 5 times a week) using a set of 4 robotic devices: Motore (Humanware); Amadeo, Diego, Pablo (Tyromotion). The training will include motor-cognitive exercises specifically selected to train spatial attention, vision and working memory, praxis, executive function, and speed of processing.
Study: NCT01558622

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: dexketoprofen trometamol
Description: 50mg intravenous infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: tramadol hydrochloride
Description: 100mg intravenous infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: pethidine hydrochloride
Description: 50mg intravenous infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: dexketoprofen trometamol + tramadol hydrochloride
Description: intravenous infusion of 50mg dexketoprofen trometamol + 100mg tramadol hydrochloride

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: dexketoprofen trometamol + pethidine hydrochloride
Description: intravenous infusion of 50mg dexketoprofen trometamol + 50mg pethidine hydrochloride

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: vitamin c
Description: 500mg intravenous infusion
Study: NCT03066336

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Erchonia LunulaLaser
Description: Active Low Level Laser Light Therapy
Study: NCT03601598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR6390
Description: SHR6390 was administered 150mg or 100mg oral daily with 3 weeks on and 1 week off
Study: NCT02609815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemigliptin/metformin
Description: zemimet-SR 50/1000 mg x 1 tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glimepiride/metformin
Description: amaryl-Mex 1/500 mg x 2 tablets
Study: NCT03496896

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TARGET
Description: The pre-discharge component includes mainly patient information, medication reconciliation, patient education, planning of a first post-discharge primary care physician visit with a timely discharge summary sent to the primary care physician. Two follow-up phone calls are made by a nurse, at D3 and D14, and include the assessment of the general health condition, the verification of the follow-up care plan, a reinforcement of the patient education, and review with the patient of the medication list with assessment of potential adverse drug events.
Study: NCT05362617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: FOLFIRI as first line chemotherapy versus mFOLFOX6 after adjuvant chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFIRI
Description: FOLFIRI as first line chemotherapy versus mFOLFOX6 after adjuvant chemotherapy
Study: NCT04028609

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy at Home
Description: In addition to receiving medical services as usual, subjects receive services from Community Healthy Workers during the transition from the hospital to their community residence.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Services as Usual
Description: Routine medical services
Study: NCT01871844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITF2984 (500, 1000, 2000 mcg bid for 7 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITF2984 (500, 1000, 2000 mcg bid for 7 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITF2984 (500, 1000, 2000 mcg bid for 7 days)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: octreotide 50 mcg tid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT00105079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saquinavir [Invirase]
Description: 1000 milligram (mg) Oral (po) twice daily (bid)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopinavir/ritonavir
Description: Lopinavir/ritonavir 400/100 mg po bid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Emtricitabine/tenofovir disoproxil fumarate
Description: Emtricitabine/tenofovir disoproxil fumarate 200/300 mg po qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine/tenofovir disoproxil fumarate
Description: Emtricitabine/tenofovir disoproxil fumarate 200/300 mg po qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: 100 mg po bid
Study: NCT00425750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: 1.6 mg/m2 through a vein on days 1 and 8 of a 21-day cycle. The first dose is given as a single agent only on Day 1 of Cycle 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: 40 mg/m2 through a vein on days 1 and 8 of a 21-day cycle except the first dose is held only on Day 1 of Cycle 1.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Tissue and blood collection.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Blood collection.
Study: NCT04283630

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Dietary nitrate in the form of beetroot juice for all participnats
Description: participants asked to consume dietary nitrate in the form of beet juice everyday in the morning and then one hour later, the vitamin C capsules.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary nitrate in the form of beetroot juice for all participnats
Description: participants asked to consume dietary nitrate in the form of beet juice everyday in the morning and then one hour later, the vitamin C capsules.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nature Made vitamin c 1000 mg
Description: vitamin C and the placebo were provided as supplement capsules. Participants were asked to consume one dose/shot of sport Beet IT (70ml) that delivers on average 300-400mg of inorganic nitrate every day in the morning during the four-week study period, except for the test days and washout weeks. Accordingly, the participant were asked to consume the daily vitamin C supplement (1000 mg) or placebo one-hour post beetroot juice supplementation.
Study: NCT01968239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: comparison of different re-treatment criteria for intravitreal injection of ranibizumab
Study: NCT04283630

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vitamin C matched Placebo capsules that made from starch.
Study: NCT00775229

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone
Description: pill, by mouth, 50mg-150mg/day for the duration of the study

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: pill, by mouth, daily
Study: NCT01435460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loteprednol etabonate 0.2%
Description: 1 drop of Alrex 4 times daily (QID) in both eyes at approximately 4 hour intervals for 2 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olopatadine 0.1%
Description: 1 drop of Patanol 2 times daily (BID)at intervals of 6-8 hours or more for 2 weeks.
Study: NCT00586820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BQ-123
Description: BQ-123 is a cyclic peptide consisting of five amino acids. BQ-123 will be infused at 300 nmol/min for 20 minutes prior to percutaneous coronary intervention (PCI).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects randomized to the placebo arm will receive a placebo infusion (saline) for 20 minutes prior to PCI.
Study: NCT03067532

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: existed simulation system user
Description: Investigator will divide the subject by the two groups. Each group will take about 15 minutes for exercising drive robotic surgery instrument by each simulation system. After 15 minutes, both group will take an short exam to check the ability to manage the robotic surgery instrument.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: home made simulator user
Description: Investigator will divide the subject by the two groups. Each group will take about 15 minutes for exercising drive robotic surgery instrument by each simulation system. After 15 minutes, both group will take an short exam to check the ability to manage the robotic surgery instrument.
Study: NCT03319732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arbaclofen
Description: Arbaclofen is the active R enantiomer of baclofen.
Study: NCT02984865

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfentanyl

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalbuphine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalbuphine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalbuphine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flubiprofen axetil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flubiprofen axetil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flubiprofen axetil

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: flubiprofen axetil

Intervention type: PROCEDURE
Group type: OTHER
Intervention: rectus sheath block
Description: Transversus abdominis plane (TAP) block combined with rectus sheath (RS) block will be applied in Group ESRD
Study: NCT02908165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: conventional TACE in combination with sorafenib, administered on a continuous schedule
Description: Patients assigned to Group A will begin sorafenib on a continuous schedule starting at 400mg BID from Cycle 1 Day 1, one week prior to cTACE treatment on Cycle 1 Day 8. After week 6, cTACE will be provided on demand (as needed, up to 4 treatments total in the first 4 cycles) at week 2 in subsequent cycles, and sorafenib will continue to be administered. Patients will be allowed to undergo dose adjustments of sorafenib as long as it remains above the ¼ dose (400mg QOD).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: conventional TACE in combination with sorafenib, administered on a sequential schedule
Description: Patients assigned to Group B will undergo cTACE up to 4 treatments within the first 4 cycles as needed prior to starting sorafenib. After it is determined that no further TACE treatment is necessary (via imaging and clinical assessment on follow-up), administration of sorafenib will begin on Day 1 of the following cycle. Dosing will begin at 400mg BID and maintained continuously provided no unmanageable toxicities develop, with follow-up assessments performed on week 6 of every 1-2 cycles as needed. Patients in Group B will also be allowed to undergo dose adjustments of sorafenib as long as it remains above the ¼ dose (400mg QOD).
Study: NCT01968239

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: comparison of different re-treatment criteria for intravitreal injection of ranibizumab
Study: NCT02039050

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aclidinium
Study: NCT03580876

Intervention type: DRUG
Group type: OTHER
Intervention: addition of azathioprine
Description: impact of addition of azathioprine after a switch of a second anti-TNF agent

Intervention type: DRUG
Group type: OTHER
Intervention: Switch to a second anti-TNF drug alone
Description: Switch to a second anti-TNF drug alone without addition of azathioprine
Study: NCT01479465

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Simtuzumab
Description: SIM administered via intravenous infusion over 30 minutes
Study: NCT01939028

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lymph node mapping
Description: Undergo lymph node mapping using isosulfan blue and/or indocyanine green solution

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sentinel lymph node biopsy
Description: Undergo SLN biopsy
Study: NCT01479465

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Simtuzumab
Description: SIM administered via intravenous infusion over 30 minutes

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Simtuzumab
Description: SIM administered via intravenous infusion over 30 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match SIM
Description: Placebo to match SIM administered via intravenous infusion over 30 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: l-Leucovorin 200 mg/m\^2 or dl-leucovorin 400 mg/m\^2 administered via intravenous infusion over 2 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: l-Leucovorin 200 mg/m\^2 or dl-leucovorin 400 mg/m\^2 administered via intravenous infusion over 2 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: l-Leucovorin 200 mg/m\^2 or dl-leucovorin 400 mg/m\^2 administered via intravenous infusion over 2 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: l-Leucovorin 200 mg/m\^2 or dl-leucovorin 400 mg/m\^2 administered via intravenous infusion over 2 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan 180 mg/m\^2 administered via intravenous infusion over 90 minutes
Study: NCT01939028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isosulfan blue
Description: Undergo lymph node mapping using isosulfan blue and/or indocyanine green solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indocyanine green solution
Description: Undergo lymph node mapping using isosulfan blue and/or indocyanine green solution
Study: NCT00281983

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT03681171

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic Dance
Description: Participants attended therapeutic ballet sessions three times per week for six weeks.
Study: NCT01479465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan 180 mg/m\^2 administered via intravenous infusion over 90 minutes
Study: NCT01939028

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo hysterectomy, bilateral salpingo-oophorectomy and/or complete pelvic lymphadenectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lymphadenectomy
Description: Undergo para-aortic lymphadenectomy
Study: NCT03282227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M207 Microneedle System
Description: M207 Microneedle System 3.8 mg
Study: NCT02792075

Intervention type: OTHER
Intervention: 5-year Follow-up

Intervention type: OTHER
Intervention: 5-year Follow-up

Intervention type: OTHER
Intervention: 5-year Follow-up

Intervention type: OTHER
Intervention: 5-year Follow-up
Study: NCT01319448

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Proguanil
Description: Proguanil tablets, 1.5mg/kg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mefloquine plus artesunate
Description: This treatment is given once a day for 3 days. Patients weighing 5-8 kg receive one paediatric tablet per day, those weighing 9-17 kg two paediatric tablets, those weighing 18-29 kg one adult tablet and those weighing 30 kg and two adult tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine plus amodiaquine
Description: amodiaquine plus sulfadoxine-pyrimethamine supervised at each bimonthly clinic visit (amodiaquine 10mg/kg per day for three days and sulfadoxine-pyrimethamine (25/1.25 mg/kg) on the first day).
Study: NCT04333667

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: The intervention consists of 8 modules. Each week participants get access to a new module. Each module consists of psychoeducation and exercise parts. Most of the exercises are based on audio records. The content of the modules includes such themes as awareness and nonjudgement of senses, emotions, and thoughts. Participants can reach a psychologist on demand.
Study: NCT04519918

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AOA
Description: AOA represents an invasive non-physiological technique.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AOA
Description: AOA represents an invasive non-physiological technique.
Study: NCT04582630

Intervention type: DIETARY_SUPPLEMENT
Intervention: omega 3 fatty acid
Description: Participants will take 0.1-0.2 g/kg/day of omega 3 fatty acids for 7 days.
Study: NCT03362905

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine topical
Description: Local anesthetic for reduction of IUD associated pain

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine topical
Description: Local anesthetic for reduction of IUD associated pain

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine topical
Description: Local anesthetic for reduction of IUD associated pain
Study: NCT01764945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 201335 (Reference)
Description: soft gelatine capsule, oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 201335 (Test)
Description: oral solution 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 201335 (Test)
Description: oral solution 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 201335 (Test)
Description: oral solution 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 201335 (Reference)
Description: soft gelatine capsule, oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 201335 (Test)
Description: oral solution 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 201335 (Test)
Description: oral solution 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 201335 (Test)
Description: oral solution 2